State Street’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-5,135,293
| Closed | -$17.5M | – | 3819 |
|
|
2018
Q3 | $17.5M | Buy |
5,135,293
+1,020,606
| +25% | +$3.68M | ﹤0.01% | 2263 |
|
|
2018
Q2 | $15.5M | Sell |
4,114,687
-1,013,536
| -20% | -$4.93M | ﹤0.01% | 2309 |
|
|
2018
Q1 | $21M | Sell |
5,128,223
-672,996
| -12% | -$3.13M | ﹤0.01% | 2020 |
|
|
2017
Q4 | $27M | Buy |
5,801,219
+2,195,723
| +61% | +$12.1M | ﹤0.01% | 1850 |
|
|
2017
Q3 | $25.6M | Buy |
3,605,496
+477,648
| +15% | +$3.43M | ﹤0.01% | 1848 |
|
|
2017
Q2 | $22.6M | Sell |
3,127,848
-351,522
| -10% | -$2.2M | ﹤0.01% | 1897 |
|
|
2017
Q1 | $21.4M | Buy |
3,479,370
+582,624
| +20% | +$3.19M | ﹤0.01% | 1896 |
|
|
2016
Q4 | $17M | Sell |
2,896,746
-665,039
| -19% | -$3.63M | ﹤0.01% | 2022 |
|
|
2016
Q3 | $18.9M | Buy |
3,561,785
+1,055,593
| +42% | +$5.69M | ﹤0.01% | 1809 |
|
|
2016
Q2 | $16.6M | Sell |
2,506,192
-401,209
| -14% | -$2.24M | ﹤0.01% | 1887 |
|
|
2016
Q1 | $13.6M | Sell |
2,907,401
-1,072,390
| -27% | -$4.28M | ﹤0.01% | 1988 |
|
|
2015
Q4 | $20.1M | Sell |
3,979,791
-2,867,944
| -42% | -$13.6M | ﹤0.01% | 1711 |
|
|
2015
Q3 | $24.1M | Buy |
6,847,735
+2,598,121
| +61% | +$17.4M | ﹤0.01% | 1636 |
|
|
2015
Q2 | $42.4M | Buy |
4,249,614
+1,008,631
| +31% | +$10.8M | ﹤0.01% | 1367 |
|
|
2015
Q1 | $41.3M | Buy |
3,240,983
+587,588
| +22% | +$7.55M | ﹤0.01% | 1355 |
|
|
2014
Q4 | $37.5M | Sell |
2,653,395
-37,976
| -1% | -$588K | ﹤0.01% | 1378 |
|
|
2014
Q3 | $37M | Buy |
2,691,371
+59,919
| +2% | +$917K | ﹤0.01% | 1332 |
|
|
2014
Q2 | $40.5M | Sell |
2,631,452
-193,452
| -7% | -$2.74M | ﹤0.01% | 1332 |
|
|
2014
Q1 | $48.1M | Buy |
2,824,904
+71,061
| +3% | +$1.07M | 0.01% | 1222 |
|
|
2013
Q4 | $35.7M | Sell |
2,753,843
-875,202
| -24% | -$10.5M | ﹤0.01% | 1383 |
|
|
2013
Q3 | $36.7M | Sell |
3,629,045
-177,745
| -5% | -$1.58M | ﹤0.01% | 1327 |
|
|
2013
Q2 | $28.4M | Buy |
+3,806,790
| New | +$29.7M | ﹤0.01% | 1420 |
|
State Street's KERX Position: Q4 2018 in Review
State Street sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 5,135,293 shares — an estimated $17.5M sold.
State Street first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $48.1M in Q1 2014. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- State Street reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- State Street sold 5,135,293 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $17.5M.
- State Street first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
- State Street's Keryx Biopharmaceuticals Inc position peaked at $48.1M in Q1 2014.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on State Street's 13F filing for Q4 2018, filed 12 Feb 2019.